TY - JOUR
T1 - Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy
T2 - Results from a multicenter study
AU - Michel, Marc
AU - Ruggeri, Marco
AU - Gonzalez-Lopez, Tomas Jose
AU - Alkindi, Salam
AU - Cheze, Stéphane
AU - Ghanima, Waleed
AU - Tvedt, Tor Henrik Anderson
AU - Ebbo, Mikael
AU - Terriou, Louis
AU - Bussel, James B.
AU - Godeau, Bertrand
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology
PY - 2020/12/24
Y1 - 2020/12/24
N2 - Management of immune thrombocytopenia (ITP) during pregnancy can be challenging because treatment choices are limited. Thrombopoietin receptor agonists (Tpo-RAs), which likely cross the placenta, are not recommended during pregnancy. To better assess the safety and efficacy of off-label use of Tpo-RAs during pregnancy, a multicenter observational and retrospective study was conducted. Results from 15 pregnant women with ITP (pregnancies, n = 17; neonates, n = 18) treated with either eltrombopag (n = 8) or romiplostim (n = 7) during pregnancy, including 2 patients with secondary ITP, were analyzed. Median time of Tpo-RA exposure during pregnancy was 4.4 weeks (range, 1-39 weeks); the indication for starting Tpo-RAs was preparation for delivery in 10 (58%) of 17 pregnancies, whereas 4 had chronic refractory symptomatic ITP and 3 were receiving eltrombopag when pregnancy started. Regarding safety, neither thromboembolic events among mothers nor Tpo-RA-related fetal or neonatal complications were observed, except for 1 case of neonatal thrombocytosis. Response to Tpo-RAs was achieved in 77% of cases, mostly in combination with concomitant ITP therapy (70% of responders). On the basis of these preliminary findings, temporary off-label use of Tpo-RAs for severe and/or refractory ITP during pregnancy seems safe for both mother and neonate and is likely to be helpful, especially before delivery.
AB - Management of immune thrombocytopenia (ITP) during pregnancy can be challenging because treatment choices are limited. Thrombopoietin receptor agonists (Tpo-RAs), which likely cross the placenta, are not recommended during pregnancy. To better assess the safety and efficacy of off-label use of Tpo-RAs during pregnancy, a multicenter observational and retrospective study was conducted. Results from 15 pregnant women with ITP (pregnancies, n = 17; neonates, n = 18) treated with either eltrombopag (n = 8) or romiplostim (n = 7) during pregnancy, including 2 patients with secondary ITP, were analyzed. Median time of Tpo-RA exposure during pregnancy was 4.4 weeks (range, 1-39 weeks); the indication for starting Tpo-RAs was preparation for delivery in 10 (58%) of 17 pregnancies, whereas 4 had chronic refractory symptomatic ITP and 3 were receiving eltrombopag when pregnancy started. Regarding safety, neither thromboembolic events among mothers nor Tpo-RA-related fetal or neonatal complications were observed, except for 1 case of neonatal thrombocytosis. Response to Tpo-RAs was achieved in 77% of cases, mostly in combination with concomitant ITP therapy (70% of responders). On the basis of these preliminary findings, temporary off-label use of Tpo-RAs for severe and/or refractory ITP during pregnancy seems safe for both mother and neonate and is likely to be helpful, especially before delivery.
UR - http://www.scopus.com/inward/record.url?scp=85098490744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098490744&partnerID=8YFLogxK
U2 - 10.1182/blood.2020007594
DO - 10.1182/blood.2020007594
M3 - Article
C2 - 32814348
AN - SCOPUS:85098490744
SN - 0006-4971
VL - 136
SP - 3056
EP - 3161
JO - Blood
JF - Blood
IS - 26
ER -